Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

OBJECTIVES: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. METHODS: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Rossetti, Barbara, Gagliardini, Roberta, Meini, Genny, Sterrantino, Gaetana, Colangeli, Vincenzo, Re, Maria Carla, Latini, Alessandra, Colafigli, Manuela, Vignale, Francesca, Rusconi, Stefano, Micheli, Valeria, Di Biagio, Antonio, Orofino, Giancarlo, Ghisetti, Valeria, Fantauzzi, Alessandra, Vullo, Vincenzo, Grima, Pierfrancesco, Francisci, Daniela, Mastroianni, Claudio, Antinori, Andrea, Trezzi, Michele, Lisi, Lucia, Navarra, Pierluigi, Canovari, Benedetta, D’Arminio Monforte, Antonella, Lamonica, Silvia, D’Avino, Alessandro, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5697828/
https://ncbi.nlm.nih.gov/pubmed/29161288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0187393
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados